ClinicalTrials.gg
Status unknownNCT04646590Updated Jan 19, 2022

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

A Phase 3 interventional study of Recombinant new coronavirus vaccine (CHO cell) group and Recombinant new coronavirus vaccine (CHO cells) placebo group in Prevention of COVID-19 and Safety and Efficacy, sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. Status unknown at 18 sites in 5 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-19.

Sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28,904
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing CHO cell in COVID-19 — 1 open to participants now, 1 under way, none of them phase 3. CHO cell · COVID-19.

Enrollment
2nd of 18
28,904 · median 714
Started
2020
with 1 other
Phase 3
7 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
8 of 18
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Among the 18 studies testing CHO cell in COVID-19, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 7 in phase 3, and was the 2nd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 18 studies testing CHO cell in COVID-19 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About CHO cell

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing CHO cell in COVID-19, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled international multicenter clinical trial design will be adopted. A total of 29,000 subjects aged 18 years and above are planned to be recruited, including 750 subjects aged 18-59 years and 250 subjects aged 60 years and above in China; 21,000 subjects aged 18-59 years and 7,000 subjects aged 60 years and above will be recruited outside China. Safety and immunogenicity will be evaluated among the Chinese subjects, and efficacy, immunogenicity and safety will be evaluated among the subjects outside China. Among them, 750 subjects aged 18-59 and 250 subjects aged 60 and above from outside China and all subjects from China will be selected as the immunogenicity subgroup for immunogenicity bridging study. The IgG levels of SARS-COV-2 neutralizing antibody and RBD protein binding antibody will be detected by blood sampling before vaccination, 14 days and 6 months after full course of vaccination to evaluate the immunogenicity and immune persistence.

Read the detailed description

After signing the informed consent form, the volunteers aged 18 years and above will receive the relevant examinations after an inquiry by investigator of the medical history (including COVID-19 history), recent medication(vaccine) history, allergy history and concomitant medications, and demographic data collection by the investigators, including physical examination (skin and mucous membranes, lymph nodes, head, neck, chest, abdomen, spine/limbs), novel Coronavirus (SARS-COV-2) nucleic acid test and antibody test, urine pregnancy (women of childbearing age) test, and vital signs (blood pressure, axillary/oral temperature, pulse) evaluation.

Screening eligible subjects will be 1:1 randomly assigned to the experimental group and the placebo control group, and vaccinated as per the 0, 1, 2 month immunization schedule.

All adverse events (AEs) up to 30 minutes after each dose of vaccination, all AEs from 0 to 7 days (including both solicited and unsolicited), and all AES from 8 to 30 days (unsolicited) will be collected; All serious adverse events (SAEs) will be collected from the first dose of vaccination to 12 months after the whole vaccination.

The incidence rate and efficacy of any severity of COVID-9 of any severity 14 days after whole vaccination.

Blood samples (5ml) will be collected before the first dose of vaccination and 14 days and 6 months after the whole course of vaccination to detect neutralizing antibody of SARS-COV-2 and protein binding antibody IgG of receptor binding region (RBD) .

03

Conditions studied

  • Prevention of COVID-19
  • Safety and Efficacy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Population aged 18 years and above;
  • Subjects voluntarily participate in the study and sign the form; and are able to provide valid identification, and understand and comply with the requirements of the trial protocol;
  • Female subjects of childbearing age agree to use effective measures from the beginning of the study to 2 months after full course of vaccination.

Exclusion criteria

Exclusion Criteria:

  • Suspected or confirmed as fever(axillary temperature ≥37.3°C / oral temperature ≥37.5°C) within 72 hours before the enrollment, or axillary temperature ≥37.3°C / oral temperature ≥37.5°C at the day of screening;
  • Diastolic blood pressure ≥ 100mmhg and / or systolic blood pressure ≥ 150mmhg;
  • Patients with previous history of a COVID-19;
  • Detection of SARS-COV-2 nucleic acid or antibody is positive;
  • Those who are suffering from the following diseases:

    1. With thrombocytopenia, any coagulation dysfunction or receiving anti-coagulatory treatment
    2. Congenital or acquired immune deficiency or disease history; no spleen, or history of splenic surgery and trauma, or receiving immunomodulator treatment within 6 months, e.g., dose of (reference dose: equivalent to 20mg/ day of prednisone, over 1 week); Or monoclonal antibodies; Or thymosin; Or interferon etc.; However, topical application (such as ointment, eye drops, inhalers or nasal sprays) is permitted;
    3. Symptoms related to acute respiratory tract infection (such as sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.);
    4. Cancer patients (except basal cell carcinoma).
  • With a history of serious allergy to any vaccine or any composition of product (including: aluminum preparations), such as allergic shock, allergic throat edema, allergic purpura, thrombocytopenic purpura, localized allergic necrosis reaction (Arthus reaction), dyspnea and angioneuroedema;
  • Inoculated with subunit vaccine and inactivated vaccine within 14 days before the first dosing of investigational vaccine, or inoculated with attenuated within 30 days;
  • Previous receiving blood transfusion or blood relevant products (including immunoglobulin) within 3 months, or planning to receive such products from the starting of study to \<6 months after the whole-course inoculation;
  • Have participated in or are participating in other covid-19 related clinical trials;
  • Women in breastfeeding period or in pregnant period (including women at childbearing age with positive result of urine pregnancy test);
  • Considered by investigators as any disease or state possibly making the subject at unacceptable risk; not conforming to the requirements of study protocol; interference of assessment of reactions of vaccine.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28,904 participants (actual)

Study arms

  • Experimental
    Investigational Vaccine

    Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 25 μg NCP-RBD protein. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.

    Biological: Recombinant new coronavirus vaccine (CHO cell) group

  • Placebo comparator
    Placebo comparator

    Placebo for Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 0.25mg Aluminum hydroxide adjuvant. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.

    Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group

Interventions

  • Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

  • BiologicalRecombinant new coronavirus vaccine (CHO cells) placebo group

    Intramuscular injection of deltoid muscle of upper arm of 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.

06

What researchers measure

Primary outcomes

  1. The endpoint of efficacy study

    The number of any severity of COVID-9 cases 14 days after whole vaccination

    Time frame: 14 days to one year after whole vaccination

  2. The endpoint of safety study

    Analysis of adverse events from the first dose of vaccination until 30 days after full course of vaccination

    Time frame: From the first dose of vaccination until 30 days after full course of vaccination

  3. The endpoint of safety study

    Analysis of serious adverse events from the first dose of vaccination until 12 months after full course of vaccination

    Time frame: From the first dose of vaccination until 12 months after full course of vaccination

Secondary outcomes

  1. The endpoint of efficacy study

    The number of severe and severity above COVID-19 cases 14 days after whole vaccination; The number of any severity of COVID-9 cases after first dose of vaccination; The number of COVID-19 cases of any severity in populations of different age group (18-59 years vs. 60 years and above) 14 days after whole vaccination.

    Time frame: Up to one year after the vaccination

  2. Endpoint of immunogenicity and immune persistence study

    The level of neutralizing antibody to SARS-COV-2 and IgG level of RBD protein binding antibody at 14 days and 6 months after full course of vaccination.

    Time frame: At 14 days and 6 months after full course of vaccination

07

Study locations

18 sites
  • Hunan Provincial Center for Disease Control and Prevention
    Changsha, Hunan 410005, China
  • Biodimed Guayaquil Clinical Research Center
    Guayaquil, Guayas, Ecuador
  • Biodimed Alemania Clinical Research Center
    Quito, Pichincha, Ecuador
  • Biodimed Eloy Alfaro Clinical Research Center
    Quito, Pichincha, Ecuador
  • Fkui-Rscm
    Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
  • FK Unpad/RSHS
    Bandung, Jawa Barat, Indonesia
  • Aziz Fatimah Hospital
    Faisalabad, Punjab, Pakistan
  • Avicenna Hospital
    Lahore, Punjab, Pakistan
  • Central Park Teaching Hospital
    Lahore, Punjab, Pakistan
  • National Hospital & Medical Center
    Lahore, Punjab, Pakistan
  • University of Health Sciences
    Lahore, Punjab, Pakistan
  • Al-Shifa Trust Eye Hospital
    Rawalpindi, Punjab, Pakistan
  • Indus Hospital and Health Network
    Karachi, Sindh, Pakistan
  • Shaheed Zulfiqar Ali Bhutto Medical University
    Islamabad, Pakistan
  • Family Hospital No.15
    Tashkent, Uzbekistan
  • GUVD Poliklinika
    Tashkent, Uzbekistan
  • IIV Markaziy Poliklinika
    Tashkent, Uzbekistan
  • Toshkent viloyat IIV Poliklinika
    Tashkent, Uzbekistan
08

References and documents

Publications

  • Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, He P, Girsang RT, Vergara H, Akram J, Satari HI, Khaliq T, Sughra U, Celi AP, Li F, Li Y, Jiang Z, Dalimova D, Tuychiev J, Turdikulova S, Ikram A, Flores Lastra N, Ding F, Suhardono M, Fadlyana E, Yan J, Hu Z, Li C, Abdurakhmonov IY, Gao GF; ZF2001 Global Trial Group. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N Engl J Med. 2022 Jun 2;386(22):2097-2111. doi: 10.1056/NEJMoa2202261. Epub 2022 May 4. PubMed 35507481 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Nov 2021, 11 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 11 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2020
First posted
Nov 30, 2020
StartActual
Dec 16, 2020
Primary completionActual
Nov 28, 2021
CompletionEst.
Dec 2022
Last update
Jan 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04646590
Responsible party
Sponsor
First posted
Nov 30, 2020
Start date
Dec 16, 2020
Primary completion
Nov 28, 2021
Completion
Dec 2022 (estimated)
Last update
Jan 19, 2022

Study contacts

Fangjun Li, Bachelor
principal investigator · Hunan Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHO cell

Start the discussion